These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24927023)

  • 1. Effective management of acute deep vein thrombosis: direct oral anticoagulants.
    Roussin A
    Int Angiol; 2015 Feb; 34(1):16-29. PubMed ID: 24927023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
    Robertson L; Kesteven P; McCaslin JE
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010956. PubMed ID: 26123214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Black SA; Cohen AT
    Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.
    Toth PP
    Vasc Health Risk Manag; 2016; 12():23-34. PubMed ID: 26929637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants and venous thromboembolism.
    Franchini M; Mannucci PM
    Eur Respir Rev; 2016 Sep; 25(141):295-302. PubMed ID: 27581829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep vein thrombosis and novel oral anticoagulants: a clinical review.
    Burgazli KM; Atmaca N; Mericliler M; Parahuleva M; Erdogan A; Daebritz SH
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3123-31. PubMed ID: 24338453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.